Literature DB >> 32640723

Cancer Patients Have a Higher Risk Regarding COVID-19 - and Vice Versa?

Franz Geisslinger1, Angelika M Vollmar1, Karin Bartel1.   

Abstract

The world is currently suffering from a pandemic which has claimed the lives of over 230,000 people to date. The responsible virus is called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and causes the coronavirus disease 2019 (COVID-19), which is mainly characterized by fever, cough and shortness of breath. In severe cases, the disease can lead to respiratory distress syndrome and septic shock, which are mostly fatal for the patient. The severity of disease progression was hypothesized to be related to an overshooting immune response and was correlated with age and comorbidities, including cancer. A lot of research has lately been focused on the pathogenesis and acute consequences of COVID-19. However, the possibility of long-term consequences caused by viral infections which has been shown for other viruses are not to be neglected. In this regard, this opinion discusses the interplay of SARS-CoV-2 infection and cancer with special focus on the inflammatory immune response and tissue damage caused by infection. We summarize the available literature on COVID-19 suggesting an increased risk for severe disease progression in cancer patients, and we discuss the possibility that SARS-CoV-2 could contribute to cancer development. We offer lines of thought to provide ideas for urgently needed studies on the potential long-term effects of SARS-CoV-2 infection.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; cancer; inflammation; oncovirus

Year:  2020        PMID: 32640723     DOI: 10.3390/ph13070143

Source DB:  PubMed          Journal:  Pharmaceuticals (Basel)        ISSN: 1424-8247


  6 in total

Review 1.  Interruption of cancer screening services due to COVID-19 pandemic: lessons from previous disasters.

Authors:  Douglas M Puricelli Perin; Tess Christensen; Andrea Burón; Jennifer S Haas; Aruna Kamineni; Nora Pashayan; Linda Rabeneck; Robert Smith; Miriam Elfström; Mireille J M Broeders
Journal:  Prev Med Rep       Date:  2021-05-17

Review 2.  COVID-19 and cancer: From basic mechanisms to vaccine development using nanotechnology.

Authors:  Hyun Jee Han; Chinekwu Nwagwu; Obumneme Anyim; Chinedu Ekweremadu; San Kim
Journal:  Int Immunopharmacol       Date:  2020-12-02       Impact factor: 4.932

3.  Time-dependent propensity-matched general population study of the effects of statin use on cancer risk in an interstitial lung disease and pulmonary fibrosis cohort.

Authors:  Jun-Jun Yeh; Jung-Nien Lai; Cheng-Li Lin; Chung-Y Hsu; Chia-Hung Kao
Journal:  BMJ Open       Date:  2021-10-11       Impact factor: 3.006

Review 4.  Cancer and COVID-19: Why are cancer patients more susceptible to COVID-19?

Authors:  Saptarshi Sinha; Chanakya Nath Kundu
Journal:  Med Oncol       Date:  2021-07-24       Impact factor: 3.064

5.  SARS-CoV-2 spike protein inhibits growth of prostate cancer: a potential role of the COVID-19 vaccine killing two birds with one stone.

Authors:  Bradley D Johnson; Ziwen Zhu; Marco Lequio; Coby G D Powers; Qian Bai; Huaping Xiao; Emerson Fajardo; Mark R Wakefield; Yujiang Fang
Journal:  Med Oncol       Date:  2022-01-20       Impact factor: 3.738

Review 6.  Immune mechanisms in cancer patients that lead to poor outcomes of SARS-CoV-2 infection.

Authors:  Muhammad Bilal Latif; Sudhanshu Shukla; Perla Mariana Del Rio Estrada; Susan Pereira Ribeiro; Rafick Pierre Sekaly; Ashish Arunkumar Sharma
Journal:  Transl Res       Date:  2021-12-03       Impact factor: 7.012

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.